Assembly Biosciences Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide. Its pipeline features long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, currently in Phase 1a/1b clinical studies targeting recurrent genital herpes caused by herpes simplex virus. The company is also advancing ABI-4334, a next-generation capsid assembly modulator in Phase 1b trials designed to disrupt the hepatitis B virus replication cycle, and ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a studies. Additional candidates include ABI-7272, a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly Biosciences Inc. leverages expertise in virology to create innovative oral therapies aimed at improving treatment outcomes for patients with chronic viral infections like hepatitis B and delta, as well as herpesviruses. Founded in 2005 and headquartered in South San Francisco, California, the company plays a key role in the biotechnology sector by addressing unmet needs in antiviral drug development.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Jason A. Okazaki J.D.

Employees

73

Headquarters

South San Francisco, CA, United States

Website

www.assemblybio.com